Similar results were also obtained for Human papillomavirus (HPV) cancer vaccine, where the recombinant fusion protein of the humanized antibody to CD40 fused to HPV16.E6/7 (αCD40-HPV16.E6/7) antigens evoked HPV16.E6/7-specific CD8+ and CD4+ T-cell responses in head-and-neck cancer patients in vitro and in human CD40 transgenic (hCD40Tg) mice (102). Here, CD40 is linked to head and neck cancer.